Evolution Research Group snaps up Finger Lakes Clinical Research for CNS trials

A MRI scan consistent with the clinical diagnosis of ALS
(By Frank Gaillard [GFDL 1.3 (www.gnu.org/licenses/fdl-1.3.html), GFDL 1.3 (www.gnu.org/licenses/fdl-1.3.html) or CC BY-SA 3.0 (http://creativecommons.org/licenses/by-sa/3.0)], via Wikimedia Commons)

Looking to boost its offerings in central nervous system trials, Evolution Research Group has bought up New York-based Finger Lakes Clinical Research.

The deal, financial details of which are not being disclosed, sees ERG take over FLCR, a clinical research facility that focuses on central nervous system trials and caters to a number of biopharmas.

The facility has worked on a host of CNS research including anxiety disorders, ADHD, depression, bipolar disorder, schizophrenia and other mental illnesses. It was founded back in 2002.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

This dovetails with ERG’s work, which also specializes in CNS disorders including Alzheimer’s, memory loss, migraine and other areas, as well as obesity, liver and kidney diseases.  

Lori Wright, CEO of ERG, said: “The addition of FLCR expands ERG's geographic capabilities in both adult and pediatric outpatient trials and further enhances ERG's growing service offerings to our clients."

Michael Farah, chairman of ERG and Partner at Linden Capital Partners (which backs the company), added: “FLCR expands ERG's footprint in growing psychiatric therapeutic areas and provides additional diversification which will allow us to further service our world-wide clients to develop important new therapies.”

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.